Research Institute for Disease of the Chest, Graduate School of Medical Science, Kyushu University, Japan Background and Aims: Malignant pleural effusion of cancer patients has been well known to be correlated with worse outcome and sign of progression disease after chemotherapy. However, we previously reported a case in which a cancer patient treated with immune checkpoint inhibitor (ICI) developed massive pleural effusion followed by remarkable tumor shrinkage. This finding suggested to us a hypothesis that pleural effusion in patients treated with ICI holds distinct immunological characteristics to enable to predict response to ICI treatment and no such analysis had been done before. Therefore, we currently have performed a multi-institutional, prospective observational study in patients who developed pleural effusion after the initiation of ICI for the development of novel therapeutic biomarkers of ICI.
Methods:
We analyzed lymphocytes in pleural effusion by flow cytometry immunologically to understand the expression of immune checkpoints and comprehensive cytokine profiles. As a control, we also analyzed pleural effusions of patients by cancer treatments other than ICIs (cytotoxic agents and TKIs). Primary objective was to reveal immunological characteristics of lymphocytes in pleural effusion of patients treated with ICI. This study was approved by each institutional review board. 
